insights_auto
Why is ABVX up 3,74%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
83,30 €
arrow_upward
+3,74%(+3,00) 1D
11 қар., 17:36:13 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
81,15 €
High
83,80 €
Low
80,65 €
Mkt. cap
7,17 млрд
Avg. vol.
111,90 м.
Volume
112,81 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
81,15 €
High
83,80 €
Low
80,65 €
Mkt. cap
7,17 млрд
Avg. vol.
111,90 м.
Volume
112,81 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
9 сағат бұрын
Abivax stock down 26% over the quarter despite its rebound
Investing.com Canada
·
1 күн бұрын
ABIVAX at Guggenheim conference: obefazimod data lift outlook By Investing.com
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 ж. 04 жел.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com